rYojbaba Co., Ltd. RYOJ
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.01
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $9.3M | $11.6M | $11.0M | — |
| Cost of revenue | $6.8M | $7.1M | $7.2M | — |
| Gross profit | $2.5M | $4.5M | $3.7M | — |
| SG&A | $2.3M | $1.7M | $1.7M | — |
| Total operating expenses | $3.2M | $2.6M | $2.4M | — |
| Operating income | -$755.4K | $1.9M | $1.3M | — |
| Interest expense | $68.0K | $77.3K | $92.9K | — |
| Pre-tax income | -$465.4K | $1.9M | $1.4M | — |
| Income tax | $584.8K | $611.0K | $616.4K | — |
| Net income | $119.4K | $1.3M | $770.6K | — |
| EPS, basic | 0.01 | 0.13 | 0.08 | — |
| EPS, diluted | 0.01 | 0.13 | 0.08 | — |
| Shares, diluted (wtd. avg.) | 10.5M | 10.0M | 10.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $6.2M | $2.6M | $4.8M | $5.4M |
| Receivables | $1.0M | $2.8M | — | — |
| Inventory | $72.5K | $66.0K | — | — |
| Total current assets | $7.7M | $6.5M | — | — |
| Property, plant and equipment | $1.5M | $1.5M | — | — |
| Other intangibles | $1.1M | $1.7M | — | — |
| Total assets | $16.9M | $16.1M | — | — |
| Accounts payable | $614.3K | $1.2M | — | — |
| Short-term debt | $687.7K | $1.3M | — | — |
| Total current liabilities | $2.8M | $4.6M | — | — |
| Long-term debt | $3.1M | $3.8M | — | — |
| Total liabilities | $10.8M | $13.5M | — | — |
| Retained earnings | $1.7M | $1.6M | — | — |
| Total equity | $6.1M | $2.5M | $1.4M | $665.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | $863.9K | $802.4K | $389.0K | — |
| Depreciation and amortisation | $461.5K | $469.3K | $333.6K | — |
| Stock-based compensation | $537.0K | — | — | — |
| Capital expenditure | $175.4K | $121.2K | $70.3K | — |
| Investing cash flow | -$175.4K | -$121.2K | $625.6K | — |
| Financing cash flow | $3.1M | -$2.4M | -$1.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-015600.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $11.0M | $11.6M | $9.3M |
| Gross profit | — | $3.7M | $4.5M | $2.5M |
| Net income | — | $770.6K | $1.3M | $119.4K |
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $9.42B | 11.4x | -6.4% |
| G | Genpact LTD | $6.86B | 13.0x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.34B | 19.1x | 2.4% |
| EXPO | EXPONENT INC | $3.68B | 37.4x | 4.2% |
| HURN | Huron Consulting Group Inc. | $3.17B | 33.5x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.09B | 81.4x | 56.4% |
| ICFI | ICF International, Inc. | $1.69B | 19.1x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $742.5M | 58.7x | 14.9% |